Aspirin, cancer, and bleeding: an equation to solve
Mené sur 3 494 patients atteints de divers cancers (gastro-œsophagien, colorectal, sein, prostate) et inclus dans 4 essais de phase III, cet essai randomisé évalue l'efficacité, du point de vue de la récidive et de la survie après un traitement anticancéreux radical, et la toxicité, notamment du point de vue des saignements, de l'aspirine en traitement adjuvant
Aspirin has been a cornerstone in the secondary prevention of cardiovascular diseases. However, its role in the primary prevention of cardiovascular disease has been questioned because adverse events such as bleeding might counteract the reduction in cardiovascular events. Nonetheless, the beneficial effects of low-dose aspirin for primary cardiovascular prevention cannot be totally excluded without considering the potential benefits in reducing the incidence and mortality of cancer, particularly gastrointestinal cancer.